| HOME >> BIOLOGY >> TECHNOLOGY |
liabilities:
Decrease (increase) in other receivables
and prepaid expenses 5 38 (604)
Increase in accounts payable and
accrued expenses 132 449 3,049
Increase (decrease) in deferred gain (200) (200) 597
--------- --------- --------
Net cash used in operating activities (13,022) (5,671) (113,609)
--------- --------- --------
CASH FLOWS FROM INVESTING ACTIVITIES:
Decrease (increase) in short-term deposits 10,660 -- (10,185)
Decrease (increase) in restricted deposits 121 (5) (44)
Investment in investment securities -- -- (3,363)
Proceeds from sales of investment securities -- -- 3,773
Proceeds from sales of trading securities 54 -- 54
Employee severance pay funds (6) (12) (915)
Purchase of property and equipment (47) (16) (4,089)
Proceeds from disposals of
property and equipment 288 33 540
Acquisition in respect of license and
purchase of assets -- -- (548)
--------- --------- --------
Net cash provided by (used in) investing
activities 11,070 -- (14,777)
--------- --------- --------
Interim Consolidated Statements of Cash Flows
for the Six Months Ended June 30, 2007 and 2006 (unaudited)(continued)
(in thousands of US dollars)
Period from
'/>"/>
SOURCE XTL Biopharmaceuticals Ltd![]() Copyright©2007 PR Newswire. |